RCS - Oxford Nanopore Tech - Plasmidsaurus collaboration and contract expansion

Oxford Nanopore TechnologiesAnnouncement

23/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240723:nRSW4347Xa&default-theme=true

RNS Number : 4347X  Oxford Nanopore Technologies plc  23 July 2024

Oxford Nanopore Technologies plc

Oxford Nanopore and Plasmidsaurus  announce collaboration and multi-year,
multi-million dollar contract expansion

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company
delivering a new generation of nanopore-based molecular sensing technology,
and Plasmidsaurus, the LA-based company that introduced overnight
whole-plasmid sequencing, today announce a new strategic collaboration to
advance plasmid sequencing beyond legacy methods, and an expanded multi-year,
multi-million dollar global contract.

Plasmidsaurus' whole-plasmid sequencing is used by researchers and industry
professionals around the world for a broad spectrum of applications, from
basic research to industrial applications, gene therapy, vaccine development,
genetic engineering and more. Its sequencing capabilities are based on Oxford
Nanopore's real-time, long-read sequencing technology, which has enabled
Plasmidsaurus to set new standards for quality and speed, delivering overnight
results and richer datasets that unlock more accurate, comprehensive, and
reliable insights.

The extension of the existing contract will see the collaboration continue to
take share of a fast-growing estimated $1.5B market opportunity in synthetic
biology as nanopore-based sequencing continues to displace traditional
methods, such as Sanger, for plasmid sequencing. Founded in 2021,
Plasmidsaurus has since opened nine labs in three countries and is expanding
its global network of 660 dropboxes and labs in key biotech hubs, including
new locations in the US, Europe, and Asia. Plasmidsaurus became an Oxford
Nanopore customer in 2021.

As strategic collaborators going forward, Oxford Nanopore and Plasmidsaurus
also intend to co-develop new technologies, reagents, and applications beyond
plasmid sequencing, including microbial and gene therapy use cases, to best
meet evolving market needs, providing further market share opportunities.

Gordon Sanghera, CEO of Oxford Nanopore commented:

"By collaborating with Plasmidsaurus, we are advancing the fields of synthetic
biology and biotechnology through the unique capabilities of nanopore
technology that are not possible with legacy methods. Our joint efforts will
drive significant market growth and deliver best-in-class sequencing services
to a global audience."

 

 ENDS 

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The company
has developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA.  The technology is used in more than 120 countries,
to understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer. Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

 

Oxford Nanopore devices sequence DNA and RNA directly and sequence short to
ultra-long fragments of DNA, for a truly comprehensive picture of the genome.
Data is streamed in real-time and can enable rapid insights.  The technology
is fully scalable - from pocket-sized to ultra-high throughput devices.

For more information please visit: www.nanoporetech.com
(http://www.nanoporetech.com)

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, the COVID-19 pandemic, delays in our
receipt of components or our delivery of products to our customers,
suspensions of large projects and/or acceleration of large products or
accelerated adoption of pathogen surveillance. These or other uncertainties
may cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRARJMATMTJTMII